<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395262</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2016-0829FX</org_study_id>
    <nct_id>NCT03395262</nct_id>
  </id_info>
  <brief_title>An Examination of a Weight Loss Formula on Health</brief_title>
  <acronym>NB14</acronym>
  <official_title>An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas A&amp;M University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine a novel weight loss formula with and without common
      stimulants on anthropometry and indices of cardiovascular disease risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity remains a problem for overall health and risk for cardiovascular disease worldwide.
      While dietary modification and increased levels of physical activity remain steadfast
      recommendations, alternative strategies related to supplementation remain an interest for the
      general populace and medical communities. A potential objection to the use of dietary
      supplements is that they often contain stimulants designed to increase metabolism. However,
      consumers and health practitioners alike are wary of such formulae; hence, the continued
      investigation of non-stimulant supplements is warranted. Therefore the aim of this study is
      to examine a novel weight loss formula with and without common stimulants on anthropometry
      and indices of cardiovascular disease risk.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Composition - Weight</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in body weight (kg) analyzed with related body composition variables via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition - Fat Mass</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in fat mass (kg) analyzed with related body composition variables via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition - Body Fat Percent</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in body fat (%) analyzed with related body composition variables via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Composition - Lean Tissue Mass</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in lean tissue mass (kg) analyzed with related body composition outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition - Bone Mass</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in bone mass (g) analyzed with related body composition outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition - Fat Free Mass</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in fat free mass (sum of lean tissue mass and bone mass expressed in kg) analyzed with related body composition variables via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition - Total Body Water</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in total body water (L and %) and analyzed with related body composition outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure - Caloric Expenditure</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in resting energy expenditure expressed in absolute (kcals/d) and relative terms (kcals/kg/day) and analyzed with related resting energy expenditure outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure - Respiratory Exchange Ratio</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in resting respiratory exchange ratio (RER) as an indicator of carbohydrate and fat oxidation analyzed with related resting energy expenditure outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measures - Waist Circumference</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in waist circumference (cm) analyzed with related anthropometric outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measures - Hip Circumference</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in hip circumference (cm) analyzed with related anthropometric outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measures - Waist to Hip Ratio</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in the ratio of waist to hip (waist / hip circumference) analyzed with related anthropometric outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measures - Body Mass Index</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in body mass index (kg of body mass / height in meters squared) analyzed with related anthropometric outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Energy Intake - Total Caloric Intake</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in caloric/energy intake (kcals/day) analyzed with related energy intake outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Energy Intake - Carbohydrate</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in dietary carbohydrate intake (grams/day and grams/kg/day) analyzed with related energy intake outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Energy Intake - Fat</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in dietary fat intake (grams/day and grams/kg/day) analyzed with related energy intake outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Energy Intake - Protein</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in dietary protein intake (grams/day and grams/kg/day) analyzed with related energy intake outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Hemodynamics - Heart Rate</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in resting heart rate (bpm) analyzed with related resting hemodynamic outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Hemodynamics - Systolic Blood Pressure</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in resting systolic blood pressure (mmHg) analyzed with related resting hemodynamic outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Hemodynamics - Diastolic Blood Pressure</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in resting diastolic blood pressure (mmHg) analyzed with related resting hemodynamic outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Glucose Homeostasis - Blood Glucose</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in blood glucose (mg/dl) analyzed with related glucose homeostasis blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Glucose Homeostasis - Fasting Insulin</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in fasting insulin (ÂµIU/mL) analyzed with related glucose homeostasis blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Glucose Homeostasis - Homeostatic Model Assessment of Insulin Resistance</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in Homeostatic Model Assessment of Insulin Resistance (Fasting insulin x Fasting glucose / 405) analyzed with related glucose homeostasis blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Lipid Profile - Triglyderides</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in triglycerides (mg/dl) analyzed with related lipid profile blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Lipid Profile - Total Cholesterol</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in total cholesterol (mg/dl) analyzed with related lipid profile blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Lipid Profile - High Density Lipoproteins</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in high density lipoproteins (mg/dl) analyzed with related lipid profile blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Lipid Profile - Low Density Lipoproteins</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in low density lipoproteins (mg/dl) analyzed with related lipid profile blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Lipid Profile - Total Cholesterol to HDL Ratio</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in the ratio of total cholesterol to high density lipoproteins (HDL) analyzed with related lipid profile blood chemistry markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Creatinine</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in creatinine (mg/dl) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Blood Urea Nitrogen</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in blood urea nitrogen (mg/dl) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Blood Urea Nitrogen to Creatinine Ratio</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in the ratio of blood urea nitrogen (mg/dl) to creatinine (mg/dl) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Alkaline Phosphatase</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in alkaline phosphatase (IU/L) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Alanine Amino Transaminase</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in alanine amino transaminase (IU/L) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Aspartate Amino Transaminase</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in aspartate amino transaminase (IU/L) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Creatine Kinase</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in creatine kinase (IU/L) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Catabolic Markers - Lactate Dehydrogenase</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in lactate dehydrogenase (IU/L) analyzed with related blood chemistry catabolic markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - White Blood Cell Counts - White Blood Cells</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in white blood cells (K/uL) analyzed with related white blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - White Blood Cell Counts - Lymphocytes</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in lymphocytes (K/uL) analyzed with related white blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - White Blood Cell Counts - Mid-Range Count</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in mid-range count (K/uL) analyzed with related white blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - White Blood Cell Counts - Granulocyte</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in granulocyte count (K/uL) analyzed with related white blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Red Cells</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in red cell count (M/uL) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Hemoglobin</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in hemoglobin (g/dl) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Hematocrit</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in hematocrit (%) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Mean Corpuscular Volume</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in mean corpuscular volume (fL) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Mean Corpuscular Hemoglobin</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in mean corpuscular hemoglobin (pg/cell) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Mean Corpuscular Hemoglobin Concentration</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in mean corpuscular hemoglobin concentration (g/dl) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Red Cell Distribution Width</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in red cell distribution width (%) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Platelet Count</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in platelet count (x103/uL) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Red Blood Cell Counts - Mean Platelet Volume</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in mean platelet volume (fL) analyzed with related red blood cell count markers of health via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry Markers of Health - Appetite Hormone - Leptin</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in leptin levels (ng/ml) analyzed via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ) - Work Domain</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in IPAQ work domain (MET minutes/week) analyzed with related IPAQ outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ) - Active Transportation Domain</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in IPAQ active transportation domain (MET minutes/week) analyzed with related IPAQ outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ) - Domestic and Garden/Yard Work Domain</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in IPAQ domestic and garden/yard work domain (MET minutes/week) analyzed with related IPAQ outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ) - Leisure-Time Domain</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in IPAQ leisure-time domain (MET minutes/week) analyzed with related IPAQ outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ) - Total Physical Activity Score</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in IPAQ leisure time domain (Total physical activity MET-minutes/week = sum of Total Work + Total Transport + Total Domestic and Garden + Total Leisure-Time MET-minutes/week scores) analyzed with related IPAQ outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Questionnaire - Perceptions of Appetite</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in perceptions of appetite assessed using using a 0 to 10 Likert scale (0 was none, 2.5 was low, 5 was moderate, and 7.5 was high, and 10 was severe) and analyzed with related satiety questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Questionnaire - Perceptions of Hunger</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in perceptions of hunger assessed using using a 0 to 10 Likert scale (0 was none, 2.5 was low, 5 was moderate, and 7.5 was high, and 10 was severe) and analyzed with related satiety questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Questionnaire - Perceptions of Satisfaction with Food</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in perceptions of satisfaction with food assessed using using a 0 to 10 Likert scale (0 was none, 2.5 was low, 5 was moderate, and 7.5 was high, and 10 was severe) and analyzed with related satiety questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Questionnaire - Perceptions of Feelings of Fullness</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in perceptions of feelings of fullness assessed using using a 0 to 10 Likert scale (0 was none, 2.5 was low, 5 was moderate, and 7.5 was high, and 10 was severe) and analyzed with related satiety questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Questionnaire - Perceptions of Diet / Eating Satisfaction</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in perceptions of diet / eating satisfaction assessed using using a 0 to 10 Likert scale (0 was none, 2.5 was low, 5 was moderate, and 7.5 was high, and 10 was severe) and analyzed with related satiety questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Questionnaire - Sleep Duration</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in average reported sleep duration over the prior 48 hours analyzed with related sleep quality questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Questionnaire - Sleep Quality</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in rating of sleep quality over the prior 48 hours analyzed with related sleep quality questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Questionnaire - Enthusiasm</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in rating of enthusiasm over the prior 48 hours analyzed with related sleep quality questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Questionnaire - Sleep Disturbances</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Changes in rating of sleep disturbances over the prior 48 hours analyzed with related sleep quality questionnaire outcomes via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Dizziness</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of dizziness using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Headache</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of headache using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Tachycardia</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of tachycardia using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Palpitations</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of palpitations using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Dyspnea</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of dyspnea using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Nervousness</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of nervousness using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Blurred Vision</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of blurred vision using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Side Effects - Other Side Effects</measure>
    <time_frame>Measured every 4 weeks for 12 weeks</time_frame>
    <description>Change in perceptions of other side effects using a Likert scale [0 (none), 1-4 (light), 5-6 (mild), 7-9 (severe), or 10 (very severe)] and analyzed with related side effect outcome measures via General Linear Model multivariate and univariate analyses and mean changes from baseline with 95% confidence intervals (CI's).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Active with caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel formula with caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active without caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novel formula without caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active with caffeine</intervention_name>
    <description>Novel formula with caffeine</description>
    <arm_group_label>Active with caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active without caffeine</intervention_name>
    <description>Novel formula without caffeine</description>
    <arm_group_label>Active without caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 25 and 34.9

        Exclusion Criteria:

          -  Recent history of weight change (+/- 10 lbs. within the past 3 months)

          -  Uncontrolled metabolic disorders

          -  Uncontrolled cardiovascular disorders

          -  Currently taking prescription medications (birth control is allowed)

          -  Currently taking dietary supplements for weight loss

          -  Pregnant or plan to become pregnant

          -  Have an intolerance to caffeine or other natural stimulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard B Kreider, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas A&amp;M University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Exercise &amp; Sport Nutrition Lab - Human Clinical Research Facility</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas A&amp;M University</investigator_affiliation>
    <investigator_full_name>Richard B. Kreider</investigator_full_name>
    <investigator_title>Executive Director, Human Clinical Research Facility</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

